| Field | Specification |
|---|---|
| Target | |
| Alternative names | N (G),N (G)-dimethylarginine dimethylaminohydrolase 1;DDAH-1;Dimethylarginine dimethylaminohydrolase 1;3.5.3.18;DDAHI;Dimethylargininase-1;DDAH1;DDAH; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the C-terminus of human DDAH1, different from the related mouse and rat sequences by one amino acid. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody detects N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 (gene DDAH1) in human, mouse and rat samples and is validated for flow cytometry, ICC/IF, IHC and Western blot. The predicted molecular weight is 31.1 kDa, and the supplier reports an observed band at about 37 kDa.
DDAH1 (dimethylarginine dimethylaminohydrolase 1) breaks down asymmetric dimethylarginine (ADMA) and monomethylarginine, endogenous inhibitors of nitric oxide synthase. By clearing these inhibitors, it supports nitric oxide production. DDAH1 is studied in vascular biology, endothelial function and cardiovascular research.
| Target | N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 (gene DDAH1; UniProt O94760, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3; plus stabilizers |
| Calculated MW | 31.1 kDa |
| Observed MW | 37 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL (Mouse, Rat) |
| Immunocytochemistry / Immunofluorescence | 2 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
Samples with a confirmed band (WB): human HUVEC cells, human HepG2 cells, human Caco-2 cells, human SH-SY5Y cells, rat brain tissue, rat liver tissue, mouse brain tissue, mouse liver tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human brain tissue, mouse brain tissue, rat brain tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): U2OS cells.
Samples with a confirmed signal (flow cytometry): A431 cells.
Immunogen
Synthetic peptide from the C-terminal region of human DDAH1. It differs from the mouse and rat sequences at one residue.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. Tissue expression noted by UniProt (human): Detected in brain, liver, kidney and pancreas, and at low levels in skeletal muscle. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Lulu Huang et al. (2025) Bupropion decreases plasma levels of asymmetric dimethylarginine and ameliorates renal injury by modulation of Ddah1, Oatp4c1, Oct2, and Mate1 in rats with adenine-induced chronic renal injury. Frontiers in Pharmacology. 10.3389/fphar.2025.1565713
